Effects of Nicotine Dependence on Multidimensional Health Outcomes

March 11, 2026 updated by: Betül Taşpınar, Izmir Democracy University

The Relationship Between Nicotine Addiction Level and Respiratory Muscle Strength, Functional Capacity, Cognitive Functions, Pain, Quality of Life, Physical Activity Level, and Sleep Quality

Nicotine, a major toxic component of cigarette smoke, together with carbon monoxide (CO), constitutes a significant environmental exposure with systemic effects. Beyond its addictive potential, chronic nicotine exposure may induce inflammation, oxidative stress, tissue hypoxia, and autonomic imbalance, potentially impairing respiratory muscle strength, functional capacity, and overall physical performance. Additionally, nicotine dependence has been associated with sleep disturbances, cognitive dysfunction, altered pain perception, and reduced quality of life.

Although previous studies have examined individual effects of smoking on specific health outcomes, research addressing these multidimensional impacts within a comprehensive framework remains limited. Therefore, this study aims to investigate the relationship between nicotine dependence level and respiratory muscle strength, functional capacity, cognitive functions, pain, quality of life, physical activity level, and sleep quality, in order to provide a more holistic understanding of the clinical consequences of nicotine dependence.

Study Overview

Status

Not yet recruiting

Detailed Description

One of the toxic components found in cigarette smoke, nicotine, together with carbon monoxide (CO), represents an important environmental exposure. Nicotine is the primary component responsible for the addictive potential of tobacco products and rapidly enters the systemic circulation, spreading to both the central and peripheral nervous systems. In addition, the systemic effects of nicotine may influence the oxygenation capacity of respiratory muscles and overall functional performance. Long-term nicotine exposure may trigger inflammatory and oxidative stress responses, which are thought to contribute to reduced respiratory muscle performance.

Sleep disturbances and attention-concentration problems associated with nicotine dependence negatively affect both quality of life and cognitive functions. Studies examining the effects of smoking status on functional capacity have shown that nicotine exposure plays a limiting role in exercise capacity and activities of daily living. One study reported that smokers had significantly lower exercise capacity and physical activity levels in daily life compared to non-smokers. The same study also demonstrated that smoking has a negative impact on the physical components of quality of life and may adversely affect functional independence.

Chronic tobacco exposure contributes to hyperalgesia through multidimensional mechanisms, including dysfunction of central pain modulation pathways, activation of proinflammatory processes, and tissue damage. Research has shown that nicotine dependence sensitizes pain perception, increases pain intensity, and complicates pain management processes. Nicotine has also been found to be directly associated with prolonged sleep latency, reduced total sleep time, and decreased slow-wave sleep, which has restorative properties. Considering that the pathophysiology of common sleep disorders has not yet been fully elucidated, we hypothesize that there may also be a relationship between CO exposure and sleep disturbances.

Chronic nicotine exposure may lead to tissue hypoxia, thereby reducing physical endurance and participation in daily activities. Furthermore, nicotine-induced mitochondrial dysfunction, oxidative stress, and autonomic imbalance may negatively affect general health perception and psychological well-being through symptoms such as fatigue, headache, and cognitive fog. Impaired sleep quality and the presence of cardiorespiratory symptoms may further limit social, occupational, and personal functioning.

Taken together, these effects suggest that nicotine dependence may lead to reductions in quality of life components and cognitive functions. Given the limited number of studies addressing the multifaceted effects of nicotine within a holistic framework, we anticipate that our study-investigating the relationship between nicotine dependence level and respiratory muscle strength, functional capacity, cognitive functions, pain, quality of life, physical activity level, and sleep quality-will contribute significantly to filling existing gaps in the literature.

Study Type

Interventional

Enrollment (Estimated)

212

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Regular cigarette use for at least the past 6 months
  • No history of respiratory, cardiovascular, or neurological/psychiatric disease
  • No recent history of surgery or trauma that could affect respiratory muscles
  • No current acute infection (especially upper or lower respiratory tract infections)

Exclusion Criteria:

  • Presence of chronic respiratory diseases such as COPD or
  • History of cardiovascular disease
  • Diagnosed neurological or psychiatric disorders
  • history of surgery or trauma affecting the respiratory muscles within the last 3 months
  • Pregnancy or suspected pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Adult Smokers
Adult individuals who use cigarettes will be enrolled in this observational study. Participants will be evaluated for nicotine dependence level using the Fagerström Test for Nicotine Dependence and will undergo assessments of respiratory muscle strength (MIP, MEP), functional capacity (6-Minute Walk Test), cognitive function (MoCA), pain (VAS/SF-MPQ), quality of life (SF-36), physical activity level (IPAQ-SF), sleep quality (PSQI), addiction behavior model (SOCRATES), and health beliefs (Health Belief Model Scale). No intervention will be applied.
Participants will undergo a comprehensive clinical assessment including evaluation of nicotine dependence level (Fagerström Test for Nicotine Dependence), respiratory muscle strength (MIP, MEP), functional capacity (6-Minute Walk Test), cognitive function (MoCA), pain (VAS and SF-MPQ), quality of life (SF-36), physical activity level (IPAQ-SF), sleep quality (PSQI), addiction behavior model (SOCRATES), and health beliefs (Health Belief Model Scale). No therapeutic intervention will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of Nicotine Dependence
Time Frame: At baseline
Nicotine dependence will be assessed using the Fagerström Test for Nicotine Dependence (FTND). The test was originally developed by Karl O. Fagerström, and its Turkish validity and reliability study was conducted in 2003. The FTND consists of six items. The total score obtained from participants' responses determines the level of nicotine dependence. Scores of 0-2 indicate very low dependence, 3-4 low dependence, 5 moderate dependence, 6-7 high dependence, and 8-10 very high dependence. This evaluation provides an important criterion for determining the need for intervention related to cigarette dependence.
At baseline
Maximal Inspiratory Pressure (MIP)
Time Frame: At baseline
Maximal inspiratory pressure will be measured using the Pony-Fx pulmonary function testing device according to ATS/ERS standards. Assessments will be performed in the seated position with a nose clip. At least three maneuvers will be obtained, and the highest value will be used for analysis. Unit of measure: cmH2O.
At baseline
Maximal Expiratory Pressure (MEP)
Time Frame: At baseline
Maximal expiratory pressure will be measured using the Pony-Fx pulmonary function testing device according to ATS/ERS standards. Assessments will be performed in the seated position with a nose clip. At least three maneuvers will be obtained, and the highest value will be used for analysis. Unit of measure: cmH2O.
At baseline
Assessment of Functional Capacity
Time Frame: At baseline
Functional capacity will be assessed using the 6-Minute Walk Test (6MWT) in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Participants will perform the test in a 30-meter corridor. Two tests will be conducted, and the longer walking distance will be used for analysis. Rest periods will be permitted and included in the total test duration. The walked distance will be expressed in meters (m). Predicted walking distance values will be calculated using standard reference equations.
At baseline
Assessment of Cognitive Functions
Time Frame: At baseline
Cognitive functions will be evaluated using the Montreal Cognitive Assessment (MoCA). MoCA is a comprehensive screening tool that assesses attention, concentration, memory, language skills, executive functions, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30, and scores of 21 and above will be considered indicative of normal cognitive function. The Turkish version has established validity and reliability.
At baseline
Assessment of Pain
Time Frame: At baseline
Pain will be evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ) to assess both qualitative and quantitative aspects of pain. The scale consists of three sections. The first section includes 15 descriptors (11 sensory and 4 affective). Participants rate each descriptor from 0 (none) to 3 (severe). The second section evaluates overall pain intensity using a visual comparison scale. The third section assesses present pain intensity on a scale from 0 (no pain) to 5 (unbearable pain). Scores will be analyzed separately as sensory, affective, and total pain scores. The Turkish version has demonstrated validity and reliability.
At baseline
Assessment of Quality of Life
Time Frame: At baseline
Quality of life will be assessed using the Short Form-36 (SF-36) Health Survey. This scale evaluates general health status across eight domains: physical functioning, role limitations due to physical problems, social functioning, role limitations due to emotional problems, vitality, pain, mental health, and general health perception. Each domain is scored from 0 to 100, with higher scores indicating better quality of life. The Turkish version has established validity and reliability.
At baseline
Assessment of Physical Activity Level
Time Frame: At baseline

Physical activity level will be assessed using the International Physical Activity Questionnaire - Short Form (IPAQ-SF). This questionnaire collects information about walking, moderate-intensity activity, vigorous-intensity activity, and sedentary time during the past seven days. It consists of seven items grouped into four sections.

Based on participants' responses, weekly physical activity levels will be calculated and classified as low, moderate, or high. Metabolic equivalent (MET) values will be used in the calculation (vigorous activity: 8 METs; moderate activity: 4 METs; walking: 3.3 METs), and weekly MET-minutes will be determined for each activity type.

At baseline
Assessment of Sleep Quality
Time Frame: At baseline
Sleep quality will be evaluated using the Pittsburgh Sleep Quality Index (PSQI). The scale consists of 24 items, 19 of which are self-rated and 5 rated by a bed partner or roommate. It includes seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored between 0 and 3, yielding a total score ranging from 0 to 21. Items completed by a partner or roommate are not included in the total score calculation. Lower total scores indicate better sleep quality. The Turkish version has demonstrated acceptable reliability.
At baseline
Addiction Behavior Model
Time Frame: At baseline
Addiction behavior will be evaluated using the Stages of Change Questionnaire (SOCRATES). This 19-item self-report scale assesses readiness to change and motivation for treatment. The Turkish version has established validity and reliability.
At baseline
Assessment of Health Behaviors
Time Frame: At baseline
Health behaviors will be assessed using the Health Belief Model Scale (HBM). The Health Belief Model is a psychosocial framework developed to understand health-related behaviors. It examines perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, and cues to action. The Health Belief Model Scale is used to measure these perceptions, and adaptations for smoking cessation behavior are available in Turkey.
At baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ferruh Taşpınar, Prof.Dr., İzmir democracy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 15, 2026

Primary Completion (Estimated)

April 15, 2027

Study Completion (Estimated)

July 15, 2027

Study Registration Dates

First Submitted

March 1, 2026

First Submitted That Met QC Criteria

March 11, 2026

First Posted (Actual)

March 16, 2026

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 11, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tobacco Use Disorder

  • University of California, San Francisco
    Tobacco Related Disease Research Program
    Recruiting
    Tobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco Abstinence
    United States
  • Washington University School of Medicine
    National Cancer Institute (NCI); National Institutes of Health (NIH)
    Completed
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditions
    United States
  • University of Utah
    National Cancer Institute (NCI)
    Recruiting
    Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Tobacco Dependence | Tobacco Chewing
    United States
  • Harvard School of Public Health (HSPH)
    Beacon Communities; The Community Builders
    Enrolling by invitation
    Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Second Hand Tobacco Smoke
    United States
  • Johns Hopkins University
    National Institute on Drug Abuse (NIDA)
    Recruiting
    Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence
    United States
  • University of California, San Francisco
    National Institute on Drug Abuse (NIDA); National Institute on Minority Health...
    Completed
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, Cigarette
    United States
  • University of California, San Francisco
    Tobacco Related Disease Research Program
    Completed
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Smoking, Tobacco | Smoking, Cigarette
    United States
  • Centre for Addiction and Mental Health
    Canadian Cancer Society (CCS)
    Recruiting
    Smoking Cessation | Tobacco Smoking | Substance Use Disorders | Nicotine Dependence | Nicotine Use Disorder
    Canada
  • Indiana University
    National Institute on Drug Abuse (NIDA)
    Recruiting
    Substance Use Disorders | Nicotine Use Disorder
    United States
  • New York State Psychiatric Institute
    Terminated
    Smoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Disorder | Nicotine Dependence | Cigarette Smoking | Tobacco Dependence | Nicotine Use Disorder | Smoking, Cigarette
    United States

Clinical Trials on Comprehensive Clinical Assessment

Subscribe